CA3142712A1 - 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds - Google Patents

2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds Download PDF

Info

Publication number
CA3142712A1
CA3142712A1 CA3142712A CA3142712A CA3142712A1 CA 3142712 A1 CA3142712 A1 CA 3142712A1 CA 3142712 A CA3142712 A CA 3142712A CA 3142712 A CA3142712 A CA 3142712A CA 3142712 A1 CA3142712 A1 CA 3142712A1
Authority
CA
Canada
Prior art keywords
group
alkyl
co2h
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142712A
Other languages
English (en)
French (fr)
Inventor
Joel Worley BEATTY
Samuel Lawrie DREW
Jeremy Thomas Andre FOURNIER
Jenna Leigh JEFFREY
Kenneth Victor LAWSON
Manmohan Reddy Leleti
Artur Karenovich MAILYAN
Guillaume MATA
Dillon Harding MILES
Jay Patrick POWERS
Ehesan Ul Sharif
Rhiannon THOMAS-TRAN
Xuelei Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcus Biosciences Inc
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of CA3142712A1 publication Critical patent/CA3142712A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0636—Irradiating the whole body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3142712A 2019-06-04 2020-06-03 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds Pending CA3142712A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857148P 2019-06-04 2019-06-04
US62/857,148 2019-06-04
PCT/US2020/035920 WO2020247496A1 (en) 2019-06-04 2020-06-03 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds

Publications (1)

Publication Number Publication Date
CA3142712A1 true CA3142712A1 (en) 2020-12-10

Family

ID=73652950

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142712A Pending CA3142712A1 (en) 2019-06-04 2020-06-03 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds

Country Status (11)

Country Link
US (1) US12410170B2 (https=)
EP (1) EP3980010A4 (https=)
JP (1) JP7665534B2 (https=)
KR (1) KR20220047247A (https=)
CN (1) CN114206332B (https=)
AR (1) AR119088A1 (https=)
AU (1) AU2020288610A1 (https=)
CA (1) CA3142712A1 (https=)
TW (1) TWI857071B (https=)
UY (1) UY38742A (https=)
WO (1) WO2020247496A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
WO2022226052A1 (en) * 2021-04-20 2022-10-27 The Regents Of The University Of Michigan Pi3k inhibitors, nanoformulations, and uses thereof
CN117295741A (zh) 2021-05-21 2023-12-26 艾库斯生物科学有限公司 Axl化合物
JP2024521712A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ阻害化合物
WO2023077046A1 (en) 2021-10-29 2023-05-04 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
CN119072476A (zh) * 2022-03-02 2024-12-03 上海海雁医药科技有限公司 六元芳环并吡咯酮衍生物、其药物组合物及应用
CA3256561A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and their uses
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
US20260028336A1 (en) 2022-07-20 2026-01-29 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024046454A1 (zh) * 2022-09-01 2024-03-07 上海海雁医药科技有限公司 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
CN119768155A (zh) 2022-09-14 2025-04-04 艾库斯生物科学有限公司 依曲地南的分散体
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
EP4604920A1 (en) 2022-10-20 2025-08-27 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20250011318A1 (en) 2023-05-25 2025-01-09 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025076299A1 (en) 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025146216A1 (zh) * 2024-01-05 2025-07-10 成都赜灵生物医药科技有限公司 六并五氮杂环酰胺类化合物及其用途
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
AU2007206860A1 (en) 2006-01-23 2007-07-26 Laboratoires Serono S.A. Thiazole derivatives and use thereof
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
MX2010005700A (es) 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
GB0812309D0 (en) 2008-07-03 2008-08-13 Ucb Pharma Sa Therapeutic agents
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
AU2010341573B2 (en) 2009-12-22 2016-10-13 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
SG10201802061TA (en) 2013-09-25 2018-05-30 Vertex Pharma A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) * 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
US10786504B2 (en) 2014-09-03 2020-09-29 Rhizen Pharmaceuticals Sa Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
AR107840A1 (es) 2016-03-10 2018-06-13 Astrazeneca Ab INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US10961236B2 (en) 2016-09-22 2021-03-30 Astrazeneca Ab (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor
CN108017641B (zh) 2016-11-02 2021-01-05 深圳铂立健医药有限公司 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
KR20240152947A (ko) 2017-10-18 2024-10-22 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체

Also Published As

Publication number Publication date
EP3980010A1 (en) 2022-04-13
CN114206332B (zh) 2024-08-23
JP2022535120A (ja) 2022-08-04
US20230024302A1 (en) 2023-01-26
US12410170B2 (en) 2025-09-09
WO2020247496A1 (en) 2020-12-10
AR119088A1 (es) 2021-11-24
JP7665534B2 (ja) 2025-04-21
AU2020288610A1 (en) 2022-01-27
CN114206332A (zh) 2022-03-18
TW202110850A (zh) 2021-03-16
UY38742A (es) 2020-12-31
TWI857071B (zh) 2024-10-01
KR20220047247A (ko) 2022-04-15
EP3980010A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US12410170B2 (en) 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds
EP3829581B1 (en) Pyridone a2r antagonists
ES2951809T3 (es) Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer
EP3618829B1 (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
AU2019229978B2 (en) Arginase inhibitors
AU2019379808B2 (en) Inhibitors of ARG1 and/or ARG2
CA3163338A1 (en) Inhibitors of hif-2alpha
CA3047600A1 (en) Azolopyrimidine for the treatment of cancer-related disorders
HK40068316A (en) 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
HK40054296B (en) Pyridone a2r antagonists
HK40054296A (en) Pyridone a2r antagonists
HK40068316B (zh) 2，3，5-三取代吡唑并[1，5-a]嘧啶化合物
HK40024629B (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
HK40024629A (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
HK40027765B (en) Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
HK40027765A (en) Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241007

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250116

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250116

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520